Skip to content
No. 033OpenRare pediatric cancerUpdated Nov 14, 2026

Can the survival curves printed in decades of small DIPG (diffuse intrinsic pontine glioma) trials be turned back into approximate patient-level data and pooled into one open, shared control group, so that the field can see whether any added treatment ever beat radiotherapy alone and can judge new single-arm trials against a fair benchmark?

Good it would do
3 / 5
Can AI help
3 / 5
How neglected
3 / 5
Can we check it
3 / 5

Why it's stuck

DIPG trials are small, mostly single-arm and very varied, so they are rarely pooled properly. A 2017 systematic review and meta-analysis of 65 studies (Hassan and others, Journal of Neuro-Oncology) said 'Meta-analyses of median overall survival results was not possible due to the lack of reported measures of variance' and that it 'is limited by the lack of adequate reporting of censored and missing participants'.

What we'd try

Find every DIPG and diffuse midline glioma trial and cohort that printed a Kaplan-Meier survival curve. Digitise the curves at scale with automated figure extraction checked by a second pass.

What could stop us

Curves rebuilt from published figures lose patient details such as H3 K27M status and age, radiotherapy-only arms are rare, and patient-level registries already serve as historical controls, so the pooled benchmark may be too noisy or already owned.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC5658459

Do you know the answer?

One reply from someone in the field can settle what our AI can't.

Members can read the full record for this problem, check its sources and comment. Open the member view →